Drug Updates

Skip to main content

Drug Updates, FDA Approvals, Prostate Cancer

Xtandi Now Approved for Metastatic Castration-Sensitive Prostate Cancer

Drug Updates, FDA Approvals

Keytruda Indicated for BCG-Unresponsive High-Risk, Non–Muscle Invasive Bladder Cancer

Drug Updates, FDA Approvals

Ayvakit First Targeted Therapy Approved for Gastrointestinal Stromal Tumors with PDGFRA Mutation

Breast Cancer, Drug Updates, FDA Approvals

Enhertu, a Dual-Targeted Therapy, Approved for Metastatic HER2-Positive Breast Cancer

Drug Updates, FDA Approvals

Padcev, a Novel Targeted Therapy, FDA Approved for Advanced or Metastatic Urothelial Cancer

Drug Updates, FDA Approvals

Tazverik First FDA-Approved Drug for Advanced Epithelioid Sarcoma Ineligible for Resection

Drug Updates, FDA Approvals, Pancreatic Cancer

Lynparza Indicated for Maintenance Treatment of Metastatic Pancreatic Cancer with BRCA Mutation

Drug Updates, FDA Approvals, In the News, Select Drug Profiles

November 11, 2019 — Oncology News & Updates

Drug Updates, FDA Approvals, Payers' Guide

FDA Approvals of Novel Brand-Name Prescription Drugs in 2018

FDA Approvals, FDA Approvals, Drug Updates, Payers' Guide

FDA Approvals of Brand-Name Prescription Drugs in 2016

1
2
3
4

Page 1 of 8
Results 1 - 10 of 80